Humanin

Humanin is a mitochondrial-derived peptide - meaning it is encoded within the mitochondrial genome itself rather than the nuclear DNA. Levels of humanin naturally fall as we age, and researchers have linked that decline to reduced cellular resilience over time. Its mechanism is cytoprotective: it protects cells from stress and programmed cell death (apoptosis), essentially helping cells survive conditions that would otherwise trigger self-destruction. Because of this action, it is used primarily in longevity-focused protocols where the goal is to support healthspan and cellular aging. A secondary goal is energy support, consistent with the mitochondrial connection. Most of the current evidence is preclinical, meaning it comes from laboratory and animal studies rather than large human trials - that context matters when weighing expectations. Humanin is taken by subcutaneous (SC) injection. Both the frequency and exact dose are set at consult, and cycles are structured as cyclical rather than continuous, with the specific length determined by your clinician. There are no current contraindications based on pregnancy status or cancer history listed for this compound, though preclinical-only evidence means individualized clinical judgment is especially important. Because most supporting data is still from animal or cellular models, a licensed provider in the PepDepo network will weigh the existing science against your specific health picture and goals before recommending or dosing this peptide. Exact dosing is always set with a licensed provider in the PepDepo network at your consult.